comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-30 16:37:24 - browse：31886

Jamy Ard (left) and Robert Lustig (right) on the 2023 STAT Breakthrough Summit stage -- coverage from STAT — Obesity experts Jamy Ard (left) and Robert Lustig speak at a panel during the 2023 STAT Breakthrough Summit. Sarah Gonzalez for STAT

Amid rising demand for drugs like Wegovy, Ozempic, and Mounjaro that can lead to significant weight loss, some obesity experts are concerned about the drugs’ costs — both to patients’ finances and to their health.

Speaking at a panel on new obesity treatments at the STAT Breakthrough Summit in San Francisco on Thursday, one expert cited a large clinical trial for Wegovy that showed that about 40% of the weight participants lost was lean mass. Side effects like nausea, vomiting, and a possible link to rare cases of pancreatitis also still plague this newest class of drugs, which imitate the effects of a hormone called glucagon-like peptide 1 (GLP) that helps people feel full.

“That’s what starvation does. You lose equal amounts of muscle and fat,” said Robert Lustig, emeritus professor of pediatrics at the University of California, San Francisco. “If you’re a person 60 years old or over and you’re losing muscle, your risk of dying just went up exponentially. So we may be … robbing Peter to pay Paul.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Why health workers in Gaza are injured or die at high rates

WSS

'Screen and refer' systems are hurting patients

Prescription digital therapeutics are key to pharma’s future

Why health workers in Gaza are injured or die at high rates

Why health workers in Gaza are injured or die at high rates

Lupron, used to halt puberty in children, may cause lasting health problems

Crowdfunding for unproven stem cell procedures spreads misinformation

focus

comprehensive

knowledge

The cancer drug shortage isn’t new — and neither are the solutions

STAT Readout Newsletter: Today's biggest biotech updates

Dobbs anniversary: the lost opportunity of abortion as health care

Researchers explore possible ties between long Covid, menopause

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Hospital price transparency does save money, advocate argues

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What affirmative action's end means to a medical student

Apple is now the first public company to be valued at $3 trillion

STAT Readout Newsletter: Today's biggest biotech updates

focus

Why health workers in Gaza are injured or die at high rates

HHS leader on health, climate change and biopharma emissions

The biotech scorecard for Q3: 15 stock

'Screen and refer' systems are hurting patients

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Eli Lilly expects to double planned employment in Boston center

focus

focus

leisure time

explore